Island Pharmaceuticals Limited (ASX: ILA) - Share Price

Current share price for ILA : $0.470 0.03 (6.82%)⁺

Island Pharmaceuticals Limited (ILA) is an ASX-listed company and is not held by any exchange traded funds (ETFs). It is focused on areas of unmet need for drugs that can address urgent viral diseases, public health or biosecurity threats. The Company is executing a dual development strategy for its assets, ISLA-101 and Galidesivir.

ILA General Information ⁺

ASX Code	ILA
Website	http://www.islandpharmaceuticals.com
Industry/Sector	Pharmaceuticals
Market Cap ($M)	139
ILA Share Price	$0.470
Day High	$0.470
Day Low	$0.445
Last Close	$0.440
ILA Share Price Movement	$0.03 ( 6.82% )

Prices as at 16:40, 4 Sep 2026

⁺Security prices are delayed by at least 20 minutes and are indicative only.

Island Pharmaceuticals Limited (ILA) Upcoming Dividends & Yields

Distribution Type	Dividend	Franking	Ex-dividend date	Payment date	Current Price⁺	Price 7D Avg	Dividend Yield
Final	10¢	0%	23 Nov 1987	18 Dec 1987	-	-	-
Interim	3¢	0%	26 May 1986	19 Jun 1986	-	-	-
Final	4¢	0%	21 Oct 1985	15 Nov 1985	-	-	-

See all dividends from Island Pharmaceuticals Limited (ILA) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

Island Pharmaceuticals Limited (ILA) price-sensitive announcements

ILA - Preliminary Final Report

Island Pharmaceuticals Limited's Preliminary Final Report for the year ended 30 June 2026

Island Pharmaceuticals Limited (ILA)
26 Aug 2026 | 3:04 PM

ILA - Island boosts Galidesivir supply as Ebola surges

Island Pharmaceuticals Limited has initiated a second manufacturing campaign to significan

Island Pharmaceuticals Limited (ILA)
21 Aug 2026 | 8:56 AM

ILA - Quarterly Appendix 4C and Activities Report

Island Pharmaceuticals Limited announced a series of strategic and operational updates in

Island Pharmaceuticals Limited (ILA)
30 Jul 2026 | 9:47 AM

ILA - Texas Biomed SOW accelerates pivotal FDA pathway

Island Pharmaceuticals Limited has executed a Statement of Work (SOW) with Texas Biomedica

Island Pharmaceuticals Limited (ILA)
13 Jul 2026 | 9:46 AM

Island Pharmaceuticals Limited (ILA) Recent ASX Announcements

Company	Sector	Market Cap ($m)	Headline	Release date/time⁺	Price at release⁺	Current price⁺	Gain/Loss
Island Pharmaceuticals Limited (ILA) ORDINARY FULLY PAID	Health Care	$139	Pivotal Marburg data secured for Galidesivir FDA pathway	31 Aug 2026 9:01AM	$0.440	$0.470	risen by 6.82%
Island Pharmaceuticals Limited (ILA) ORDINARY FULLY PAID	Health Care	$139	Appendix 4G and Corporate Governance Statement	26 Aug 2026 3:16PM	$0.460	$0.470	risen by 2.17%
Island Pharmaceuticals Limited (ILA) ORDINARY FULLY PAID	Health Care	$139	Annual Report to shareholders	26 Aug 2026 3:16PM	$0.460	$0.470	risen by 2.17%
Island Pharmaceuticals Limited (ILA) ORDINARY FULLY PAID	Health Care	$139	Preliminary Final Report	26 Aug 2026 3:04PM	$0.460	$0.470	risen by 2.17%
Island Pharmaceuticals Limited (ILA) ORDINARY FULLY PAID	Health Care	$139	Island boosts Galidesivir supply as Ebola surges	21 Aug 2026 8:56AM	$0.460	$0.470	risen by 2.17%
Island Pharmaceuticals Limited (ILA) ORDINARY FULLY PAID	Health Care	$139	Date of AGM & Closing Date for Director Nominations	13 Aug 2026 9:21AM	$0.460	$0.470	risen by 2.17%

ILA Financial Summary

Year to Jun	NPAT	EPS	EPS chg (%)	Yield (%)	Franking (%)
2026A	-$9.84	-$3.60	61.10%	0.00%	0.0%
2025A	-$3.92	-$2.30	-28.70%	0.00%	0.0%
2024A	-$2.86	-$3.20	2.30%	0.00%	0.0%

ILA Peer Comparison

Company	Mkt Cap	EPS Growth (%)			P/E (%)			Dividend Yield (%)
Company	Mkt Cap	2024 A	2025 A	2026 A	2024 A	2025 A	2026 A	2024 A	2025 A	2026 A
Clarity Pharmaceuticals Ltd (CU6)	$847M	0.4454	0.0000	0.0000	0.0000	0.0000	0.0000	0.00%	0.00%	0.00%
Island Pharmaceuticals Limited (ILA)	$130M	0.6106	0.0000	0.0000	0.0000	0.0000	0.0000	0.00%	0.00%	0.00%
Neuren Pharmaceuticals Limited (NEU)	$2,608M	-0.7857	0.2462	0.9655	88.3971	70.9310	36.0877	0.00%	1.60%	1.90%

ILA Market Comparison

	Earnings	P/E Ratio	P/B Ratio	P/E Growth
Company	0.00	0.00	10.33	0.00
Market	0.35	13.60	1.17	0.81
Sector	0.66	31.20	3.01	2.67

ILA Directors

Name	Position	Start Date
Dr David Foster	Chief Executive Officer, Managing Director, Executive Director	1 Oct 2020
Mr Jason Alan Carroll	Non-Executive Chairman, Non-Executive Director	2 Jul 2025
Mr Christopher Ntoumenopoulos	Non-Executive Director	19 Sep 2024

Island Pharmaceuticals Limited (ILA) Changes in Directors' Interest & Trades

Date of change	Director	Buy/Sell	Security Type	Qty	Trade Price	Value
3 Dec 2025	CARROLL, Jason	Exercise	Options	974,930	$0.070	$68,245.100
3 Dec 2025	NTOUMENOPOULOS, Christopher	Buy	Indirect Shares	844,568	$0.070	$59,119.760
3 Dec 2025	CARROLL, Jason	Buy	Direct Shares	974,930	$0.070	$68,245.100

See all changes in directors' interest & trades for Island Pharmaceuticals Limited (ILA) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

ILA Management

Name	Position
Cameron Jones	Chief Financial Officer,Company Secretary

ILA Substantial Shareholders

Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Island Pharmaceuticals Limited (ILA). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.

Holding	Name
41,690,073 (16.86%)	William James Garner
31,100,000 (12.58%)	Jason Alan Carroll
19,264,773 (8.25%)	MWP Partners Limited
14,010,000 (5.67%)	Daniel Tillett

ILA Calendar of Events

Date	Event
25 August 2027	Report (Annual)
25 August 2027	Report (Prelim)
24 February 2027	Report (Interim)
08 October 2026	AGM

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.

What our members say about us